This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
The participant provides written informed consent
≥ 18 years of age on day of signing informed consent.
Participant with histologically or cytologically confirmed diagnosis of advanced unresectable and/or metastatic solid tumors
A male participant must agree to use contraception and refrain from sperm donation or expecting to father a child
A WOCBP who has a positive serum pregnancy test (within 72 hours) prior to treatment.
Has received prior investigational agents within 4 weeks prior to treatment.
Has received anti-cancer chemotherapy (Immunotherapy (non-antibody-based therapy), retinoid therapy, hormonal therapy within 2 weeks prior to treatment.
Has received antibody-based anti-cancer therapy within 4 weeks prior to treatment.
NextCure, Inc.
Lead sponsor
LigaChem Biosciences, Inc.
Collaborator